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Aims Measurement of NT-proBNP and copeptin may help identify those at high risk of heart failure (HF). However the value of
NT-proBNP and copeptin has been little studied in the older population in primary care. This study aims to examine the
use of NT-proBNP and copeptin in improving risk prediction and stratification of HF in older men with and without car-
diovascular disease (CVD).
Methods
and results
This was a prospective study of 3870 men aged 60–79 years with no diagnosed HF followed up for a mean period of 11
years, during which there were 254 incident HF cases. NT-proBNP was associated with HF in those with and without
established CVD [diagnosed myocardial infarction (MI), angina, or stroke]. NT-proBNP improved prediction beyond
routine conventional risk factors (age, obesity, diabetes, hypertension, history of MI, and history of angina) and the
Health ABC Heart Failure Score in all men and in men with and without established CVD (P,0.0001 for improvement
in c-statistics). The net reclassification index (NRI) beyond conventional risk factors was 18.8% overall (27.4% for men
without CVD and 17.4% for men with CVD). In contrast, copeptin was associated with HF in men with CVD only and
did not improve prediction of HF after inclusion of conventional risk factors (P ¼ 0.95 for improvement in c-statistics).
Conclusion NT-proBNP, but not copeptin significantly improves prediction and risk stratification of HF beyond routine clinical para-
meters obtained in general practice settings in older men both with and without established CVD.
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Introduction
Heart failure (HF) constitutes a major and increasing burden of mor-
bidity and mortality in older people, leading to high healthcare costs.
Identifying high risk individuals to target HF prevention in primary
care remains a priority. Current guidelines have stimulated efforts
to focus on identifying those with stage A (presence of risk factors)
and stage B HF (asymptomatic ventricular dysfunction detectable
on echocardiography), in order to implement early interventions
to prevent progression to stage C (overt HF).1 Although echocardi-
ography provides effective non-invasive assessment of HF, routine
echocardiographic screening is expensive and not currently recom-
mended for use in the general population.2 The optimal strategy
for identifying people at high risk in the general population remains
unclear, though the use of blood markers in primary care settings
to identify those at high risk of developing HF is potentially
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promising.3 The aetiology of HF involves interplay between myocar-
dial ischaemia and remodelling, fibrosis, inflammation, and neurohor-
monal activation.4 NT-proBNP, a peptide released frommyocardium
in response to ventricular wall stress and dysfunction, has emerged as
a strong predictor of incident HF in high risk populations5 and in the
general population.6 –12 In recent years, there has been interest in the
neurohormones in the cascade of the arginine vasopressin (AVP) axis
in the pathogenesis of HF.4,13 Plasma C-terminal provasopressin
(copeptin), the C-terminal part of the AVP precursor peptide, is a
vasoconstrictor that is secreted from the posterior pituitary in re-
sponse to changes in plasma osmolarity and reduced cardiac
output as part of a defence mechanism to preserve circulatory
homeostasis.4,13 Copeptin has been established as a reliable
marker of circulating AVP concentration in routine clinical prac-
tice.4,13 Higher levels of copeptin have been associated with
increased risk of death in patients with HF,13,14 and copeptin has
been shown to predict HF in patients with prior myocardial infarction
(MI).15 A recent report has highlighted the potential value of com-
bined measurements of copeptin and NT-proBNP in elderly patients
presenting in primary care with early symptoms of HF in predicting
cardiovascular disease (CVD) mortality.14 However, copeptin was
not shown to predict HF in the general middle-aged population,8
and the use of copeptin in predicting HF in the elderly, where most
cases of HF occur, has not been established.
While NT-proBNP has improved prediction of HF beyond estab-
lished routine clinical risk factors6– 8,10– 12 and the Health ABC Heart
Failure Score,12,16 the use of NT-proBNP testing in older adults (.60
years old) with and without CVD has been less studied, particularly in
a primary care setting. We have thereforeexamined the clinical utility
of NT-proBNPand copeptin in an elderly population of men with and
without prevalent CVD. We assessed each biomarker’s ability to
improve the prediction of HF beyond established clinical HF risk
factors (and Health ABC Heart Failure Score) and to what extent
they add predictive information beyond inflammatory markers
which have been shown to improve risk prediction for HF.17
Finally, we assessed the performance of NT-proBNP and copeptin
in improving risk stratification for incident HF.
Methods
The British Regional Heart Study is a prospective study involving 7735
men aged 40–59 years drawn from one general practice in each of 24
British towns, who were screened between 1978 and 1980.18 The popu-
lation studied was socio-economically representative of British men and
comprises predominantly white Europeans (.99%). In 1998–2000, all
surviving men, then aged 60–79 years, were invited for a 20th year
follow-up examination, on which the current report is based. Ethical ap-
proval was obtained from all relevant local research ethics committees,
and informed consent has been obtained from the subjects. All men com-
pleted a mailed questionnaire providing information on their lifestyle and
medical history, had a physical examination, and provided a fasting blood
sample. The samples were frozen and stored at –208C on the day of col-
lection and transferred in batches for storage at –708C until analysis,
carried out after no more than one freeze–thaw cycle. The 12-lead
ECGs were recorded using a Siemens Sicard 460 instrument and were
analysed using Minnesota Coding definitions at the University of
Glasgow ECG core laboratory.19 The men were asked whether a
doctor had ever told them that they had angina or MI, HF, or stroke;
details of their medications were recorded at the examination. A total
of 4252 men (77% of available survivors) attended for examination.
Blood measurements, including NT-proBNP and copeptin, were avail-
able in 3985 men (94%) at the 20-year follow-up examination (1998–
2000). Of these men, we excluded 115 men with prevalent HF, leaving
3870 men for analysis.
Cardiovascular risk factors at 1998–2000
Details of measurement and classification methods for smoking status,
body mass index, physical activity, social class, alcohol intake, blood pres-
sure, blood lipids, and forced expiratory volume in 1 s (FEV1) in this
cohort have been described.20222 C-reactive protein (CRP) was
assayed by ultrasensitive nephelometry (Dade Behring, Milton Keynes,
UK). Predicted glomerular filtration rate (eGFR), a measure of renal func-
tion, was estimated from serum creatinine using the Modification of Diet
in Renal Disease equation developed by Levy et al.;23 eGFR ¼ 186 ×
creatinine21.154 × age20.203. Electrocardiographic LV hypertrophy
(LVH) was defined according to relevant Minnesota codes (codes 3.1
or 3.3). Atrial fibrillation was defined according to Minnesota codes
8.3.1 and 8.3.3.
Laboratory methods
Manufacturers’ calibrators andcontrolswereused in themeasurementof
NT-proBNP and copeptin in accordance with their instructions.
NT-proBNP was determined using the Elecsys 2010 electrochemilumi-
nescence method (Roche Diagnostics, Burgess Hill, UK).24 The lower
limit of sensitivity was 5 pg/mL. Low control coefficient of varaition
(CV) was 6.7% and high control CV was 4.9%. Data on NT-proBNP
were available in 3672 men. Copeptin was measured using an ultrasensi-
tive method on a BRAHMS Kryptor compact plus (B.R.A.H.M.S, Botti-
sham, UK). The lower limit of sensitivity was 0.9 pmol/L. Low control
CV was 4.7% and high control CV was 4.6%. Data on copeptin were avail-
able in 3560 men.
Follow-up
All men have been followed up from initial examination (1978–1980) for
cardiovascular morbidity,25 and follow-up has been achieved for 99% of
the cohort. In the present analyses, all-cause mortality and morbidity
events are based on follow-up from re-screening in 1998–2000 at
mean age 60–79 years to June 2010, a mean follow-up period of 11
years (range 10–12 years). During this period, 1278 men had died. Sur-
vival times were censored at date of HF, death from any cause, or end
of the study follow-up period (June 2010), whichever occurred first.
Fatal coronary heart disease (CHD) events were defined as death with
CHD [ International Classification of Diseases (ICD) 9th revision,
codes 410–414] as the underlying code. A non-fatal MI was diagnosed
according to World Health Organization criteria. Evidence of non-fatal
MI and HFwasobtainedbyad hoc reports from general practitioners sup-
plemented by biennial reviews of the patients’ practice records (including
hospital and clinic correspondence) through to the end of the study
period. Incident non-fatal HF was based on a confirmed doctor diagnosis
of HF from primary care records and confirmed by a review of available
clinical information from primary and secondary care records (including
symptoms, signs, investigations, and treatment response) to ensure that
the diagnosis was consistent with current recommendations on HF diag-
nosis.26 The incidence and determinants of HF cases identified using this
process have already been reported and are consistent with results from
other studies.22 Incident HF included incident non-fatal HF as well as
death from HF (ICD 9th revision code 428).
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Statistical methods
The distribution of NT-proBNP and copeptin was skewed, and log trans-
formation was used. Cox’s proportional hazards model was used to
assess the multivariate-adjusted hazards ratio (HR) (relative risk) in a
comparison of quarters of NT-proBNP (copeptin) and for a 1 standard
deviation increase in log NT-proBNP (log copeptin). In multivariate ana-
lyses, smoking [never, long-term ex-smokers (.15 years), recent
ex-smokers (,15 years), and current smokers], social class (manual vs.
non-manual), physical activity (four groups), alcohol intake (five
groups), diabetes (yes/no), use of antihypertensive treatment (yes/no),
pre-existing MI (yes/no), LVH (yes/no), and AF (yes/no) were fitted as
categorical variables. Systolic blood pressure, FEV1, CRP, eGFR, and
NT-proBNP were fitted as continuous variables. Receiver operating
characteristic (ROC) curves and areas under the curve (AUC)
(c-statistics) were used to assess the ability of NT-proBNP (copeptin)
to predict HF beyond a score which included conventional routine risk
factors as well as how NT-proBNP predicted beyond the Health ABC
Heart Failure Score. Conventional routine risk factors included estab-
lished risk factors for HF routinely obtained in clinical practice, e.g. age,
obesity, hypertension, history of diabetes, history of MI, and history of
angina. The Health ABC Heart Failure Score includes age, smoking,
eGFR, heart rate, LVH, albumin, systolic blood pressure, history of MI
and angina, fasting blood glucose, and antihypertensive treatment.16
We calculated risk function estimates based on the regression coeffi-
cients of the Cox’s models with and without NT-proBNP (copeptin) in
the model. Tests for differences between the c-statistics for established
risk function models with and without NT-proBNP (copeptin) were per-
formed using an SAS macro (%ROC) with SAS software (version 9.3). To
address the issue of how NT-proBNP evaluation may alter the risk strati-
fication of men, all men were categorized according to three risk groups
based on their 10 year predicted probabilities, ,10%, 10–19%, and
≥20%, obtained from risk function models for HF events with and
without NT-proBNP. The 20% cut-off was used as it is estimated that life-
time risk for developing HF is 20%.27 We evaluated the ability of
NT-proBNP to reclassify risk by calculating the net reclassification im-
provement (NRI) and the integrated discrimination improvement
(IDI).28 We also examined the prognostic value of NT-proBNP in
healthy normal subjects, HF stage A subjects (those with traditional
risk factors for CVD but without established CVD or HF),1 and men
with pre-existing established CVD (MI, stroke, or angina) based on a pre-
vious doctor diagnosis of one or more of these conditions. Stage A sub-
jects included those with obesity, hypertension, cigarette smoking,
dyslipidaemia (statin use), or diabetes1 (n ¼ 2411). Healthy normal
included those with none of these risk factors and without pre-existing
CVD (n ¼ 645).
Results
Table 1 shows baseline characteristicsof the study population.During
the mean follow-up period of 11 years, there were 257 incident HF
cases (5.9/1000 person-years) in the3870menwith nopreviousdiag-
nosed HF. Mean (geometric) NT-proBNP and copeptin were signifi-
cantly higher in those with pre-existing CVD (MI, angina, or stroke)
(186.8 vs. 81.5 pg/mL; P,0.0001 and 4.33 vs. 3.92 pmol/L; P ¼
0.0006, respectively) than men without CVD. The 99th percentiles
for NT-proBNP in those with and without CVD were 3254 and
1752 pg/mL and the corresponding 99th percentiles for copetin
were 36.42 and 22.24 pmol/L, respectively.
Figure 1 shows the Kaplan–Meier estimates of the cumulative inci-
dence of HF by quarters of NT-proBNP and copeptin in all men. Risk
of HF increased significantly with increasing quarters of NT-proBNP
(log rank testP,0.0001) and toaweakerextent with increasingquar-
ters of copeptin (log rank test P ¼ 0.002).
In all men, risk of HF increased significantly by NT-proBNP quar-
ters after adjustment for age, smoking, physical activity, social class,
alcohol intake, systolic blood pressure, prevalent diabetes, history
of CHD (angina or MI), use of antihypertensive treatment, and LVH
(Table 2). Further adjustment for eGFR, CRP, albumin, FEV1, heart
rate, and ECG evidence of ischaemia and silent MI had minor
effects on the findings. When examined separately in men with and
without CVD, the strong positive association between NT-proBNP
and HFwasbroadly comparable in bothgroups (Table2). Exclusionof
men who developed a non-fatal MI during the follow-up period made
minor differences to the findings (data not shown). Raised
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Table 1 Baseline characteristics in 3870 men with no
diagnosed heart failure
Parameters Value
Mean age 68.61 (5.51)
Current smoking 12.8%
Ex-smokers 58%
Inactive 10.6%
Manual 53.7%
Heavy drinkers 3.8%
BMI, kg/m2 26.84 (3.62)
History of MI 10.0%
Silent MI (ECG only) 2.6%
History of angina 13.0%
History of diabetes 6.9%
Stroke 5.2%
Use of antihypertensive drugs 32.6%
Hypertensives 70.7%
Statin use 6.9%
Left ventricular hypertrophy 7.7%
Atrial fibrillation 3.4%
Systolic BP, mmHg 149.34 (24.0)
Diastolic BP, mmHg 85.34 (11.07)
Cholesterol, mmol/L 6.01 (11.08)
HDL-cholesterol, mmol/L 1.32 (0.34)
Glucose, mmol/L 5.87 (5.25–6.10)
FEV1, L 2.60 (0.65)
eGFR, mL/min/1.73 m2 72.29 (12.62)
Heart rate, b.p.m. 65.72 (12.66)
Albumin, g/L 44.15 (2.73)
C-reactive protein, mg/L 1.72 (0.82–3.43)
NT-proBNP, pg/mL 97.51 (46–189)
Copeptin, pmol/L 3.81 (2.44–6.23)
All results are given as either percentage, mean (SD), or median and interquartile
range.
BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration
rate; FEV1, forced expiratory volume in 1 s; MI, myocardial infarction.
Hypertensive, systolic BP ≥140 or diastolic BP ≥90 or on blood-lowering
treatment.
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NT-proBNP (i.e. top quarter) was associated with a markedly
increased risk of HF in healthy normal men, in those with stage A
risk factors, and in men with CVD [adjusted HR 3.34, 95% confidence
interval (CI) 1.93–5.70; P,0.0001; HR 2.25, 95% CI 1.91–2.65;
P,0.0001; and HR 2.13, 95% 1.71–2.65; P,0.0001, respectively].
Copeptin correlated significantly but only modestly with
NT-proBNP(r ¼ 0.18; P,0.0001). Elevatedcopeptin was associated
with increased risk of HF, but this was markedly attenuated after
adjustment for conventional risk factors and was no longer significant
after further adjustment for blood markers (model 2; Table 3). When
stratified by presence of CVD, copeptin was only associated with risk
of HF in those with CVD after adjustment for routine clinical risk.
However, this association was also attenuated to borderline signifi-
cance after adjustment for additional risk factors (model 2) and was
completely abolished after further adjustment for NT-proBNP (1
SD increase in log copeptin HR 1.09, 95% CI 0.84–1.41; P ¼ 0.48).
Figure1 Kaplan–Meier curvesof cumulative heart failure (HF) incidence by quartiles of NT-proBNP(,42, 42–77, 78–151,≥152 pg/mL) and by
quartiles of copeptin (,2.46, 2.46–3.85, 3.86–6.32, ≥6.33pmol/L) in men without prevalent HF.
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In contrast, the association between NT-proBNP remained highly
significant after adjustment for copeptin (1 SD increase in log
NT-proBNP HR 2.04, 95% CI 1.56–2.69; P,0.0001).
Table 4 shows the c-statistics for the conventional risk score and
the Health ABC Heart Failure Score, and the improvement in
c-statistics in models with and without NT-proBNP, copeptin, or
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 N-terminal pro brain natriuretic peptide and incident heart failure risk in men with no diagnosed heart failure
Adjusted HR (95% CI)
Age only Model 1 Model 2 Model 3
All men (n ¼ 3672; 250 cases)
1 (,42) 1.00 1.00 1.00 1.00
2 (42–77) 3.23 (1.69–6.16) 2.91 (1.52–5.58) 2.83 (1.48–5.43) 2.85 (1.49–5.47)
3 (78–151) 4.27 (2.27–8.06) 3.51 (1.85–6.64) 3.39 (1.79–6.42) 3.38 (1.78–6.41)
4 (≥152) 14.22 (7.78–25.98) 9.87 (5.31–18.33) 9.02 (4.84–16.80) 8.51 (4.54–15.89)
1 SD increase in log NT-proBNP 2.42 (2.16–2.72) 2.21 (1.93–2.53) 2.15 (1.88–2.48) 2.21 (1.93–2.53); 2.26 (1.93–2.65)a
P,0.0001 P,0.0001 P,0.0001 P,0.0001
Men with no CVD (n ¼ 2903; 153 cases)
1 SD increase in log NT-proBNP 2.24 (1.93–2.60) 2.17 (1.87–2.52) 2.14 (1.81–2.54) 2.01 (1.66–2.43); 1.97 (1.62–2.38)a
P,0.0001 P,0.0001 P,0.0001 P,0.0001
Men with CVD (n ¼ 769; 97 cases)
1 SD increase in log NT-proBNP 2.22 (1.75–2.82) 2.33 (1.84–2.96) 2.12 (1.63–2.75) 2.42 (1.82–3.21); 2.73 (2.01–3.72)a
P,0.0001 P,0.0001 P,0.0001 P,0.0001
Missing data on NT-proBNP; n ¼ 198.
1 SD log NT-proBNP ¼ 1.16.
Model 1: adjusted for age, smoking, physical activity, social class, alcohol intake, LV hypertrophy, systolic blood pressure, antihypertensive drugs, history of MI, angina,
Model 2: adjusted for model 1 + eGFR + FEV1 + albumin + CRP.
Model 3: model 2 + heart rate, AF, ECG evidence of ischaemia and silent MI.
CI, confidence interval; CRP, C-reactive protein; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; FEV1, forced expiratory volume in 1 s; MI, myocardial
infarction.
aExclude incident MI.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Copetin and incident heart failure risk in men with no diagnosed heart failure
Adjusted HR (95% CI)
Age only Model 1 Model 2
All men (n ¼ 3560; 234 cases)
1 (,2.46) 1.00 1.00 1.00
2 (2.46–3.85) 1.10 (0.73–1.65) 1.04 (0.69–1.56) 1.03 (0.68–1.55)
3 (3.86–6.32) 1.44 (0.99–2.12) 1.27 (0.86–1.87) 1.17 (0.79–1.73)
4 (.6.32) 1.72 (1.18–2.51) 1.35 (0.92–1.99) 1.18 (0.79–1.76)
1 SD increase in log copeptin 1.31 (1.12–1.54) 1.19 (1.04–1.52) 1.13 (0.97–1.42)
P ¼ 0.001 P ¼ 0.01 P ¼ 0.09
Men with no CVD (n ¼ 2807; 139 cases)
1 SD increase in log copeptin 1.20 (1.01–1.65) 1.07 (0.87–1.40) 1.02 (0.85–1.23)
P ¼ 0.03 P ¼ 0.45 P ¼ 0.81
Men with CVD (n ¼ 753; 95 cases)
1 SD increase in log copeptin 1.43 (1.19–1.72) 1.33 (1.10–1.61) 1.24 (0.99–1.53)
P ¼ 0.0002 P ¼ 0.003 P ¼ 0.06
Missing data on copeptin n ¼ 310.
1 SD log copeptin ¼ 0.71.
Model 1: adjusted for age, smoking, physical activity, social class, alcohol intake, LV hypertrophy, systolic blood pressure, antihypertensive drugs, history of MI, angina.
Model 2: adjusted for model 1 + eGFR + FEV1 + albumin + CRP.
CI, confidence interval; CRP, C-reactive protein; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; FEV1, forced expiratory volume in 1 s; MI, myocardial
infarction.
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CRP. NT-proBNP(but neither copeptin nor CRP) added significantly
to HF prediction beyond either risk score. Adding NT-proBNP to a
model which included conventional risk factors and CRP provided
significant improvement in prediction (P≤0.0001). When examined
separately by presence of CVD, NT-proBNP added significantly to
HF prediction beyond conventional risk factors and the Health ABC
Heart Failure Score in men both with and without CVD (P,0.0001)
(Table 4). Neither copeptin nor CRP improved prediction beyond
conventional risk factors in men with or without CVD (data not
shown). A model in those with CVD which included conventional
risk factors and NT-proBNP showed no improvement on addition
of copeptin (c-statistic ¼ 0.721, 0.668–0.775 vs. 0.725, 0.673–0.776
without copeptin; evidence for improvement P ¼ 0.78).
We assessed the degree of reclassification occurring for HF
prediction for a score based on established HF risk factors with
NT-proBNP compared with a score based on established HF risk
factors alone. The NRI in all men was estimated at 18.8% for
NT-proBNP (P,0.0001). The NRI in non-events was –6.0% and
the NRI in events was +24.8%. The IDI was also significant (0.076;
P,0.0001). Similar NRIs were obtained if the Health ABC Heart
Failure Score was used. We also examined the NRI separately in
men with and without CVD. In men without CVD, the NRI was
estimated at 27.4% (P,0.0001) (–5.5% and +32.9% in non-events
and events, respectively) and for men with CVD the estimated NRI
was 17.4% (P,0.0001) (+9.4% and +8.0% in non-events and
events, respectively). IDIs of 0.082 and 0.062 were obtained for
those with and without CVD, respectively (P,0.0001).
Discussion
In this study of older men, NT-proBNP markedly improved predic-
tion of HF beyond the established Health ABC Heart Failure Score
and beyond established routine clinical parameters, whereas copep-
tin and CRP did not. NT-proBNP improved sensitivity in the predic-
tion of HF, and thus improved risk classification among those who
experienced HF. Our finding extends those of previous studies by
examining the prognostic value of NT-proBNP and improvement
in risk prediction in those with and without CVD separately within
the same general older population and comparing the predictive
value of NT-proBNP with other markers including in particular
copeptin, but also CRP. The findings that NT-proBNP improved pre-
diction even in asymptomatic men suggests that it is detecting men
with subclinical cardiac dysfunction (or capturing other risk pathways
relevant to HF risk) in men not considered to be at elevated risk.
The association between NT-proBNP and HF is not explained by
conventional risk factors for HF; symptoms of general poor health
(lung function, renal dysfunction, and inflammation), heart rate, and
presence of AF or evidence of ischaemia on ECG, and the association
is not mediated by the development of an MI. NT-proBNP has been
shown to be associated with the development of AF,8 a strong risk
factor for HF. We did not have information on AF during follow-up
and it is possible that part of the association may be mediated by
the development of AF. Although we did not have echocardiographic
measures, previous studies have shown the association between
NT-proBNP and HF to be independent of LV mass.11
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Table 4 Improvement in c-statistics for conventional models and the Health ABC Heart Failure Score models with and
without N-terminal pro brain natriuretic peptide, copeptin and C-reactive protein
c-Statistics P-value improvement
All men
ABC risk score 0.706 (0.672–0.739) –
ABC risk score + NT-proBNP 0.764 (0.735–0.794) P,0.0001
Conventional risk factors 0.708 (0.676–0.741) –
Conventional risk factors + NT-proBNP 0.768 (0.739–0.798) P,0.0001
Conventional risk factors + copeptin 0.704 (0.670–0.740) P ¼ 0.95
Conventional risk factors + CRP 0.706 (0.672–0.739) P ¼ 0.67
Conventional risk factors + CRP + NT-proBNP 0.773 (0.744–0.800) P,0.0001
Men with no CVD
ABC risk score 0.677 (0.635–0.722) –
ABC risk score + NT-proBNP 0.753 (0.715–0.792) P,0.0001
Conventional risk factors 0.684 (0.642–0.727) –
Conventional risk factors + NT-proBNP 0.760 (0.723–0.799) P,0.0001
Men with CVD
ABC risk score 0.704 (0.650–0.758) –
ABC risk score + NT-proBNP 0.744 (0.695–0.792) P ¼ 0.03
Conventional risk factors 0.663 (0.608–0.718) –
Conventional risk factors + NT-proBNP 0.725 (0.673–0.776) P ¼ 0.004
Conventional risk factors include age obesity, hypertension, history of diabetes, history of MI, and history of angina.
ABC score includes age, smoking, eGFR, heart rate, LV hypertrophy, albumin, systolic blood pressure, history of MI and angina, fasting blood glucose, and antihypertensive treatment.
CRP, C-reactive protein; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction.
S.G. Wannamethee et al.30
Measurement of NT-proBNP is not currently recommended for
CHD risk assessment in asymptomatic adults.28 While several
studies have evaluated the performance of NT-proBNP for the
purpose of reclassifying HF risk in the general population,628,10 –
12 few have examined the performance of NT-proBNP separately
in those without established CVD and in those with established
CVD. Our study suggests that measurement of NT-proBNP
improves risk prediction and stratification over models that con-
sider clinical variables alone as well as the Health ABC Heart
Failure Score in both asymptomatic men and men with established
CVD. Of interest, work in part from our group suggests that
NT-proBNP deserves greater consideration for general CVD risk
screening.24,30 If this was to happen, concomitant screening for
HF using NT-proBNP would be logical. Although measurement of
NT-proBNP is currently expensive, it is likely that the assay cost
will come down when NT-proBNP commercial patents expire
and the assay is routinely available and used for general CVD risk
screening.
In contrast, copeptin showed much weaker associations with HF
than NT-proBNP in this older population and was not associated
with increasedHF risk in menwith CVD after taking into account clin-
ical risk factors and NT-proBNP. Although copeptin has been shown
tobe a potentially useful prognosticmarkerof mortality in addition to
NT-proBNP and in addition to high-sensitivity troponin in HF
patients,14,31 copeptin was not a useful predictor of HF in this
general older population without HF. This is consistent with a previ-
ous report showing no association between copeptin and HF in a
middle-aged population.10 The majority of men in this study
(96.9%) had levels below the reference limit (97.5 percentile) of
16.8 pmol/L seen in a healthy population.32 Thus copeptin does
not appear topredict incident HF, but raised copeptin is a useful prog-
nostic marker when HF is present and in those in whom the majority
(. 55%) were seen to have levels above this reference range.31
Our study is not without some limitations. It was basedon anolder,
predominantly white, male population of European origin, so that the
results cannot be generalized directly to women, or to younger
populations or other ethnic groups. The current findings are based
on doctor-diagnosed HF, which is likely to underestimate the true
incidence of HF in this study population. However, the other risk
factor associations with HF risk in this report and in our previous
report on obesity and HF22 generally agree with previous data and
therefore suggest potential external validity for our findings. Echo-
cardiographic measurements were not carried out in the present
study and we were not therefore able to differentiate systolic and
diastolic HF. Like other studies,628,10 –12 our reclassification model
is not based on any current clinical guidelines, although it serves to
illustrate the way in which NT-proBNP might usefully improve risk
models as they develop.
In conclusion, we have shown that NT-proBNP but, importantly,
not copeptin significantly improves prediction and risk stratification
of HF beyond routine clinical parameters obtained in general practice
settings in both older men with and without established CVD, sug-
gesting potential for optimizing chronic HF therapy or to prevent
its development. Further large studies are needed to determine the
practicality and process as well as the potential cost-effectiveness
of performing NT-proBNP testing in selected older adults in the
general population to detect high risk subjects for HF.
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